Last updated on January 2020

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Brief description of study

This study will evaluate the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML).

Clinical Study Identifier: NCT03280030

Find a site near you

Start Over

Novartis Investigative Site

Hirakata-city, Japan
  Connect »